Piper Jaffray Cos. set a $33.00 price objective on Reata Pharmaceuticals Inc. (NASDAQ:RETA) in a report published on Friday morning. The brokerage currently has a a buy rating on the stock.

Several other equities analysts also recently weighed in on RETA. Cowen and Company started coverage on shares of Reata Pharmaceuticals in a report on Monday, June 20th. They set an outperform rating and a $22.00 target price for the company. Citigroup Inc. started coverage on shares of Reata Pharmaceuticals in a report on Monday, June 20th. They set a buy rating and a $32.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Reata Pharmaceuticals from a hold rating to a buy rating and set a $22.00 target price for the company in a report on Saturday, August 27th.

Reata Pharmaceuticals (NASDAQ:RETA) traded up 3.45% during midday trading on Friday, hitting $30.00. 30,092 shares of the stock were exchanged. The firm has a 50 day moving average of $23.82 and a 200-day moving average of $20.12. Reata Pharmaceuticals has a 12-month low of $11.03 and a 12-month high of $32.22. The stock’s market cap is $669.75 million.

Reata Pharmaceuticals (NASDAQ:RETA) last posted its earnings results on Thursday, August 11th. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. The business had revenue of $12.40 million for the quarter. On average, equities analysts expect that Reata Pharmaceuticals will post ($0.54) earnings per share for the current year.

In related news, Director R Kent Mcgaughy, Jr. bought 308,220 shares of the firm’s stock in a transaction that occurred on Thursday, August 18th. The shares were acquired at an average cost of $17.08 per share, with a total value of $5,264,397.60. Following the completion of the transaction, the director now owns 25,004 shares of the company’s stock, valued at $427,068.32. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Colin John Meyer bought 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The stock was bought at an average cost of $16.26 per share, for a total transaction of $113,820.00. Following the completion of the transaction, the insider now directly owns 27,172 shares of the company’s stock, valued at approximately $441,816.72. The disclosure for this purchase can be found here. Company insiders own 62.40% of the company’s stock.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

5 Day Chart for NASDAQ:RETA

Receive News & Stock Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.